Abstract Body

ACTG 5327 (‘SWIFT-C’) is an ongoing study of sofosbuvir (SOF)-based treatment of acute Hepatitis C virus (HCV) in HIV-infected individuals. We previously reported that participants in Cohort 1 of SWIFT-C taking SOF and ribavirin had 4.3-fold (range 1.4-15.8) higher intracellular tenofovir-diphosphate (TFV-DP) concentrations in dried blood spots (DBS), but there are no data with SOF and the HCV NS5A inhibitor, ledipasvir (LDV). The objective of this analysis was to compare TFV-DP concentrations in red blood cells (RBC) measured with DBS and tenofovir (TFV) concentrations in plasma before, during, and after LDV/SOF treatment in participants in Cohort 2 of SWIFT-C.

Plasma and DBS were obtained from participants taking tenofovir disoproxil fumarate (TDF). TFV-DP was measured in those with available samples at entry, weeks 2 and 8 of LDV/SOF treatment and 2 (EOT+2), 4 (EOT+4), 8 (EOT+8), and 12 weeks (EOT+12) following completion of LDV/SOF treatment. For the 12 participants with data through EOT+12, TFV-DP was also measured at weeks 1 and 4 to provide additional information on the kinetics of the interaction. TFV in plasma was measured at entry, week 8 and EOT+12. TFV and TFV-DP were log transformed for analysis and compared at each visit to study entry using paired t-tests.

19 participants (5 Hispanic, mean±SD age 43.7±8.4yrs, weight 77.4±10.2kg, and CrCl 106.1±24.4 mL/min) were taking a TDF-based antiretroviral (ARV) regimen prior to commencing 8 weeks of LDV/SOF. Geometric mean TFV-DP and TFV concentrations are shown in the table. At weeks 1, 2, 4 and 8 of LDV/SOF treatment, TFV-DP was 7.1, 9.7, 16.7 and 16.6-fold higher in DBS, respectively compared with study entry (all p < 0.001). By EOT + 12, TFV-DP concentrations were similar to baseline (p=0.39). Plasma TFV levels were 1.9 fold higher at week 8 vs. study entry (P=0.0014) and similar between study entry and EOT+12 (P=0.56).

After 8 weeks of LDV/SOF treatment, TFV-DP concentrations in DBS were increased 16.6-fold and TFV in plasma was increased 1.9 fold. TFV-DP accumulated rapidly in DBS after starting LDV/SOF (more than doubling within the first week), but declined consistent with the 17-day half-life in RBC after LDV/SOF therapy was completed. This suggests enhanced RBC loading during LDV/SOF therapy. Additional studies are needed to determine the mechanism, magnitude in other cell types, and clinical significance of this interaction.